Pelthos Therapeutics Q2 revenue rises on Zelsuvmi adoption - PTHS News | RalliesPelthos Therapeutics Q2 revenue rises on Zelsuvmi adoption
P
PTHS• Outlook
- Pelthos expects further growth for Zelsuvmi, with over 4,200 units dispensed in July.
- Company plans to commercialize Xepi in Q1 2027 and Xeglyze in Q3 2027.
- Pelthos believes current cash and potential Horizon facility funds will support its business plan.
Revenue drivers
- Zelsuvmi adoption - Co said growing adoption and increased prescriptions of Zelsuvmi drove Q2 revenue growth.
- Milestone and royalty expenses - Q2 expenses rose due to two non-recurring sales-based milestones and higher royalty costs.
- Inventory write-off - Q2 cost of goods sold included a $0.9 mln write-off of commercial API inventory after quality control testing.
Analyst coverage
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and .
no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy".Wall Street's median 12-month price target for Pelthos Therapeutics Inc is $55.00, about 90.2% above its August 12 closing price of $28.91.Quarterly results
- U.S. biopharmaceutical firm's Q2 net product revenue grew 45% quarter-over-quarter.
- Net loss for Q2 narrowed compared to Q1, and adjusted EBITDA loss also improved.
- Company expenses rose due to milestone payments and inventory write-offs in Q2.
| Metric | Actual |
|---|
| Q2 Net Loss | $23.42 mln |
| Q2 Adjusted EBITDA | -$5.70 mln |
| Q2 Operating Income | -$17.32 mln |
•
